intrODuctiOn BK virus (BKV) is a DNA virus from the Polyomaviridae family discovered in the early 1970s and named after the initials of a Sudanese renal transplant patient whose urine contained the virus that was isolated in cell culture. [1] The initial infection with BKV causes asymptomatic infection or a mild respiratory illness during childhood. The virus then remains latent in various sites such as renal epithelial cells and peripheral blood mononuclear cells. [2] In immunocompetent individuals, the cellular immunity acts on various antigenic targets of BKV, eliciting an effective immune response especially involving CD4 T-cells. [3] These cells have a large multiplicative capacity and release a wide range of cytokines, especially interferon, thereby effectively limiting the viral replication. [4] In immunosuppressed individuals, especially when the cellular immunity is depleted, there is reactivation of the latent BKV. This along with its unrestricted replication causes viral shedding in urine and blood. [3, 5] The viral genome has three main regions, namely the early gene region coding for regulatory proteins, the late gene region coding for capsid proteins (VP1, VP2 and VP3) and the non-coding control region (NCCR). The latter region is conventionally divided into five blocks, O, P, Q, R and S, with the O block containing the origin of replication and transcription binding sites, while the rest of the blocks have the promoters of transcription. The division of base pairs among the various blocks of NCCR (O142 bp, P63 bp, Q39 bp, R63 bp and S63 bp) has arbitrarily been done such that an archetypal ww-NCCR strain has been proposed. Any variations in this archetypal NCCR region in the form of Purpose: BK virus (BKV) is an opportunistic pathogen which causes significant morbidity and mortality in individuals who are immunodeficient. We aimed to quantitate and characterise BKV and to correlate with the degree of immunosuppression among human immunodeficiency virus (HIV)-1-infected individuals. Methods: BKV DNA detection was carried out using an in-house quantitative real-time polymerase chain reaction on paired whole-blood and urine samples collected from 187 antiretroviral therapy (ART)-naïve HIV-1-infected individuals and 93 healthy individuals who served as controls. Sequencing was performed for a proportion of high BK viral load (VL) samples to observe non-coding control region (NCCR) rearrangements. Results: BKV positivity in urine was 25.6% among HIV-infected individuals and 10.7% in control individuals (P = 0.03). The BK VL showed a significant negative correlation with CD4+ T-cell counts, a positive correlation with WHO clinical staging and no significant correlation with HIV-1 VL. Of 42 BKVs from urine samples sequenced, two showed rearrangements without clinically severe disease or high VL. Their NCCR and VP1 sequence-based genotyping revealed genotype I. In a small subset of individuals (n = 8) on ART who were being followed up, six individuals showed either decrease or complete clearance of virus with ART. Conclusion: There was a higher frequency of BK viruria in HIV-1-infected individuals than among healthy controls and the positivity correlated with the degree of immunosuppression. There was no association of high VL with NCCR rearrangements in urine.
point mutations, deletions or duplication are considered as the rearranged rr-NCCR. [6] This is found to be associated with clinically severe and histologically evident disease [7] with elevated viral load (VL). [8] There are four genotypes of BKV based on the VP1 and NCCR hypervariable region which are designated as I, II, III and IV. Genotype I is the most common type worldwide. [9, 10] The disease progression usually correlates with the degree of immunosuppression. [11] The immunosuppression-related BKV diseases and the characterisation of the NCCR region are well studied among transplant patients. [12] However, the role of BKV in human immunodeficiency virus (HIV) infection and the viral characteristics are not well studied. There are only few case reports of varied clinical spectrum that has been available in the literature. [13] [14] [15] [16] Hence, the aim of this study was to analyse the frequency of BKV from whole-blood and urine samples among antiretroviral therapy (ART)-naïve HIV-infected individuals and to correlate the BK VL with CD4 count and clinical findings (WHO disease staging) and also to characterise the NCCR region in a proportion of the BKV-positive cases.
matErials anD mEtHODs
The study commenced after obtaining approval from the Institutional review board. Urine and whole-blood samples were collected from 187 HIV-1-infected individuals and 93 age-and sex-matched healthy individuals (one control for two patients) following informed consent. The urine samples were processed and stored as aliquots at −70°C. Eight HIV-1-infected individuals were followed up after ART for a minimum of 3 months.
Detailed clinical information (age, sex, demographics and HIV-related opportunistic infections [OIs]) was collected from the individuals' hospital charts for classification into the various WHO clinical stages. The CD4+ T-cell counts for the study samples were performed using the standard procedures on the BD FACS Count system (Becton, Dickinson, San Jose, USA). [17] For the BKV detection, DNA was extracted from whole-blood and urine samples using the commercially available QIA amp DNA blood mini kit (Qiagen, Hilden, Germany) as per the manufacturer's instructions. [18] An in-house validated qualitative real-time polymerase chain reaction (PCR) assay was carried out on the study samples for BKV with primer and probe sequences specific for VP1 gene, [19] as shown in Table 1 , which showed no cross-reactivity with JC virus or other DNA viruses. [20, 21] BKV plasmid was used as the source of positive control. [20] Sterile Milli-Q ® water (Burlington, Massachusetts, US) control was included after every 5 th place to check the PCR cross-contamination. Real-time PCR was carried out using Rotor gene RG-3000 or RG-6000 (Corbett Research, Mortlake, Victoria, Australia). Samples positive for BK virus by Qualitative real time PCR were subjected to in-house real time quantitation PCR was tested by in-house real-time quantitation PCR. The PCR standards were prepared using plasmid cloned using Topo TA Clone/TOP10 kit (Invitrogen, Carisbad, USA) for the target. The plasmids were quantitated using the DNA spectrophotometry (BioTek Instruments, Vermont, USA) and then diluted serially in tenfold dilutions using MilliQ ® water to obtain 106 -102 copies/µl. Quantification of viral DNA was carried out using the same protocol as qualitative PCR with respective primers and probes. The thermal cycling conditions used were same as those for qualitative PCR. The sensitivity of BKV quantitative real-time PCR was ≤1 plasmid/ml. [20, 21] The same extracted DNA utilised for real-time PCR was used for genotyping and analysis of BKV NCCR rearrangement from a proportion of BKV-positive samples to determine the prevalent genotypes and to look for NCCR rearrangements. The amplification of the NCCR region was carried out in the nested PCR format with primer sequences, taken from published literature, [7] as shown in Table 1 . The sequences in the form of electropherograms were bidirectionally aligned using the Finch TV software version 1.4.0 (Geospiza Inc., a subsidiary of Perkin Elmer Inc., Waltham, US) and Bioedit sequence editor 7.0.9.0 (Tom Hall, Ibis Biosciences, Carlsbad, CA, USA). These bidirectionally aligned sequences were utilised for phylogenetic analyses using neighbour joining method with 1000 bootstrap replicates in MEGA4 software (version 4.0, http://www.megasoftware.net). [22] An in-house endogenous retrovirus (ERV)-3 qualitative real-time PCR was carried out to check the DNA integrity for all PCR-negative urine and blood samples. [20, 21] The plasma HIV-1 VL was determined for all BKV DNA-positive samples (n = 46) and for a proportion of BKV-negative samples (n = 56) selected randomly using Artus RealArt™ HIV-1 assay in Rotor-Gene™ 6000 (Wesville, South Africa). [23] 
Statistical analysis
The Chi-square and the two-tailed t-tests were used to analyse the difference in the proportion of BKV positivity and VL between HIV-1-infected and HIV-uninfected individuals.
The Spearman's test was used to determine the correlation coefficient. Box-and-whisker plots were then generated using the Medcalc software version 9.2.0.1 (http://www.medcalc. be). One-way analysis of variance as well as univariate and multivariate analyses of all data were performed using Epi Info 6 version 6.04b (CDC, Atlanta, GA) and STATA 10.0 (Stata Corp, College Station, TX, USA), respectively. P < 0.05 was considered statistically significant. Of the 93 healthy individuals, 10 (10.7%) urine samples were positive for BKV DNA with VL ranging from 1 to 572 copies/ml (mean VL -107 copies/ml). The BKV positivity and their VL in urine among HIV-1-infected and healthy individuals showed significant difference (P = 0.003 and 0.02, respectively).
Of 187 whole-blood samples from HIV-1-infected individuals, only 2 (1%) were positive for BKV DNA with 1 copy/ml each. All healthy individuals' blood samples were negative for BKV. ERV-3 was amplified for all negative samples (blood and urine). The frequency of BKV positivity and their VL among the study samples is shown in Table 2 .
Comparing BKV positivity with WHO staging, BK VL showed significant difference (P = 0.005) with higher VL in symptomatic group stages (2, 3 and 4) than in asymptomatic stage 1. The univariate analysis of BK VL outcome showed significant negative correlation with CD4+ T-cell counts (P = 0.026) and a positive correlation with WHO clinical staging (P = 0.002). The variables which were significant by univariate analysis were only subjected for multivariate analysis. They showed significant correlation only with WHO clinical staging (P = 0.007) and not with CD4 counts (P = 0.64) as shown in Table 3 .
Eight HIV-1-infected individuals were followed up after a minimum of 3 months of ART. Of them, six (75%) individuals showed an effective response of either decrease in BK VL (n = 2, 25%) or negativity for BKV (n = 4, 50%), while the remaining two showed an increase in BK VL with ART [ Table 4 ]. The NCCR sequencing and genotyping was carried out on 41 BKV DNA-positive urine samples. Two archived ART-naïve BKV-positive samples from a previous study from our institution were also sequenced to analyse rearrangements in blood. NCCR rearrangement was observed from two urine samples (one ART-naïve patient and one follow-up patient) and from both archived whole-blood samples. The rearrangement pattern seen in our clinical urine strains comprised of duplication of a part of P (9 bp) and Q (23 bp) blocks of BKV NCCR. The archived blood samples showed duplication of almost the whole of P (60 bp) and Q (35 bp) blocks in one sample and duplication of a part of P (51 bp) and Q (28 bp) blocks in the other sample as shown in Figure 1 . All the samples were genotype I based on the NCCR sequences; these were submitted to the GenBank database and were given accession numbers KT728853-KT728896.
Table 2: The number of BK virus-positive urine and whole-blood samples and their mean viral load among human immunodeficiency virus-1-infected and human immunodeficiency virus-negative healthy individuals

DiscussiOn
OIs often occur due to reactivation from latency among immunocompromised individuals. [11] BKV has been shown to be one of the important agents that can lead to high morbidity among transplant recipients. [24] In renal transplant settings, the BKV-associated disease starts with viruria and with unrestricted multiplication due to immunosuppression leads to viral shedding in peripheral blood. [25] The frequency of BK viremia has been reported to be about 20% after 1 year of transplantation. [26] Viremia is considered to be a predicting factor for the development of nephropathy which occurs usually 1-12 weeks post-transplant, finally leading to allograft failure. [27] This increased shedding of virus in blood and associated nephropathy very rarely occurs in immunocompromised states other than renal transplantation. There was no sample data available on BK viruria and viremia among HIV-infected individuals and its association with immunosuppression or stage of the disease.
Table 4: CD4 counts, human immunodeficiency viral load and BK viral load values (urine) before and after antiretroviral therapy in follow-up patients
Study number
Pre-ART values
Post-ART values
CD4 count (cells/µl)
HIV load (copies/ml)
BK VL (copies/ml)
CD4 count (cells/µl)
HIV load (copies/ml) BK VL (copies/ml) 15 In this study, the frequency of BK viruria was significantly higher in HIV-1-infected individuals (25.6%) than healthy controls (10.7%). This frequency observed was almost the same (24%) as described by Sundsfjord et al. [28] but lower (57.7%) than described in Ledesma et al's. study. [2] The rate of viremia was not comparable with other studies as the sample matrix and treatment status were different. In our previous studies, we reported a similar frequency of viremia from whole-blood samples (0.6%) with no positivity in cerebrospinal fluid and brain tissue samples of HIV-infected individuals. [20, 29] The frequency (1%) and VL of BKV observed among HIV-infected individuals are significantly low compared to that reported among transplant patients (20%) following immunosuppression. [26] The association between CD4 counts and frequency of viruria or BK VL remains debatable. There are studies which reported that BK viruria is independent of CD4 counts with no correlation between CD4 counts and viruria or VL. [28, 30, 31] In this study, the BK VL showed a significant positive correlation with WHO clinical staging and a negative correlation with CD4+ T-cell counts, demonstrating the association of BKV viruria with the extent of immunosuppression as evidenced by other studies. [21, 32] However, there was no significant correlation between BKV and HIV VL. In our study, HIV-1-infected individuals who had high BK VL did not manifest any clinical features specific to BKV.
As BKV is an important opportunistic infectious agent, restoration of immune system plays a vital role among HIV-1-infected individuals, which is accomplished by implementation of highly active ART (HAART) alone. [19] Akhgari et al. reported the percentage positivity of BK viremia in HAART-experienced individuals to be much lower than treatment-naïve HIV-infected individuals. [30] This holds well in this study as with the small subset of ART-experienced individuals followed up, most of them had either a decrease or complete clearance of the virus.
The majority of studies on the NCCR region were conducted among renal transplant recipients. A study from Italy reported major rearrangements in urine (12%), blood (23%) and renal biopsy (27%) samples. However, they did not find any association of rearrangements with the degree of nephropathy or viral replication (evidenced by decoy cells). [33] They also reported no association between NCCR changes with BK viruria or viremia. [34] In our study, the association of NCCR rearrangement with high BK VL was found with viremia but not with viruria as evidenced by Gosert et al. [7] The most frequently seen genotype of BKV worldwide is genotype I. [5, [35] [36] [37] [38] Similar to these studies, our genotyping, which was based on NCCR, revealed all strains to be genotype I.
cOnclusiOn
The frequencies of BK viruria as well as the mean VL are higher among HIV-1-infected individuals than HIV-negative healthy individuals and there is a significant correlation between the extent of immunosuppression and BKV viruria. Unlike in transplant patients, the viremia is negligible among HIV-infected individuals irrespective of immunosuppression. Although there was no association between NCCR rearrangements with high BK VL in urine or clinically BKV-specific severe disease, individuals with NCCR rearrangements in blood had low CD4 counts and higher BK VL.
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